

The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and meta-analysis

Mrzljak, Anna; Cigrovski Berković, Maja; Giovanardi, Francesco; Quirino, Lai

Source / Izvornik: **Croatian Medical Journal, 2022, 63, 176 - 186**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.3325/cmj.2022.63.176>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:823316>

Rights / Prava: [Attribution-NonCommercial-NoDerivatives 4.0 International/Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-11-23**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine Digital Repository](#)



Croat Med J. 2022;63:176-86
<https://doi.org/10.3325/cmj.2022.63.176>

The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and meta-analysis

Aim To evaluate the effect of diabetes mellitus type 2 (T2DM) on the outcomes after treatment of hepatocellular carcinoma (HCC).

Methods PubMed and Cochrane Central Register of Controlled Trials Databases were systematically searched. Three HCC clinical outcomes were explored: death, progressive disease after locoregional therapies, and recurrence. Sub-analysis was performed according to the use of potentially curative (resection, transplantation, thermo-ablation) or non-curative therapies. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to compare the pooled data between T2DM and non-T2DM groups.

Results A total of 27 studies were analyzed. Overall, 85.2% of articles were from Asia. T2DM was associated with an increased risk of death (OR 3.60; 95%CI 2.18-5.95; $P < 0.001$), irrespective of the treatment approach: curative (OR 1.30 95%CI 1.09-1.54; $P = 0.003$) or non-curative (OR 1.05; 95%CI 1.00-1.10; $P = 0.045$), increased HCC recurrence (OR 1.30; 95%CI 1.03-1.63; $P = 0.03$), and increased disease progressiveness (OR 1.24; 95%CI 1.09-1.41; $P = 0.001$).

Conclusions Current data provide strong evidence that T2DM unfavorably affects HCC progression and recurrence, and patients' survival after treatment, irrespective of the approach used.

Anna Mrzljak^{1,2}, Maja Cigrovski Berković³, Francesco Giovanardi⁴, Lai Quirino⁵

¹Department of Gastroenterology and Hepatology, University Hospital Center Zagreb, Zagreb, Croatia

²University of Zagreb School of Medicine

³Department of Endocrinology, Diabetes, Metabolism and Clinical Pharmacology, University Hospital Dubrava, Zagreb, Croatia

⁴General Surgery and Organ Transplantation Unit, Department of Surgery, Sapienza University of Rome, Rome, Italy

⁵Sapienza University of Rome, Rome, Italy

Received: June 18, 2021

Accepted: December 23, 2021

Correspondence to:

Maja Cigrovski Berković
Department of Endocrinology,
Diabetes, Metabolism and Clinical
Pharmacology
University Hospital Dubrava
Avenija Gojka Šuška 6
10000 Zagreb, Croatia
maja.cigrovskiberkovic@gmail.com

The prevalence of hepatocellular carcinoma (HCC) associated with non-alcoholic fatty liver disease (NAFLD) is increasing (1,2) as the result of the globally increased prevalence of NAFLD, which is estimated to be about 25% (3). NAFLD patients have a two- to three-fold increase in the risk of developing diabetes mellitus type 2 (T2DM), and the risk is even higher in those with more severe hepatic disease and fibrosis (4-6). On the other hand, patients with T2DM have a higher prevalence of non-alcoholic steatohepatitis (NASH), liver fibrosis, and end-stage liver disease (7).

Several studies have documented the relation between T2DM and the incidence of different cancer types, while the data on the relationship between T2DM and increased risk of incident HCC seem especially robust and clinically reliable (8-10). Observational studies suggest higher mortality of patients developing HCC in the presence of T2DM (11,12). On the other hand, data from meta-analyses suggest that both the risk and prognosis of patients with HCC and diabetes might be influenced by the type of anti-diabetic treatment, where metformin, unlike sulphonylurea, potentially protects against cancer and leads to better prognosis in case of cancer development (13,14).

The underlying mechanisms linking T2DM and HCC are still under scientific scrutiny. However, the interconnections between metabolic derangements characteristic for T2DM, obesity, and NAFLD suggest that insulin resistance on the hepatic and systemic level and the release of pro-inflammatory cytokines, vasoactive factors, and pro-oxidant molecules are potentially implicated in the development and progression of HCC.

With the intent to gain a better insight into this issue, we performed a meta-analysis to evaluate the effect of T2DM on poor outcomes after HCC treatment. To explore several different clinical settings, three outcomes of interest were investigated: death, progressive disease after locoregional therapies, and recurrence. Moreover, sub-analyses were performed according to the use of potentially curative (resection, transplantation, thermo-ablation) or non-curative therapies.

MATERIALS AND METHODS

Search sources and study design

A systematic review of the published literature was undertaken focusing on the role of T2DM in the outcomes of HCC patients receiving any tumor therapy. The search

strategy followed the Preferred Reporting Items for Systemic Reviews and Meta-Analysis (PRISMA) guidelines (15). In terms of inclusion criteria, data extraction, quality assessment, and statistical analysis, we used the same methodological approach as in our previous article (16).

The research question formulated in the present study included the following Patients, Intervention, Comparator, Outcome components:

Patient: patients with HCC and T2DM;

Intervention: any HCC therapy;

Comparison: patients with HCC without T2DM treated with the same approach;

Outcome: death, progressive disease, or recurrence.

We searched the PubMed and Cochrane Central Register of Controlled Trials databases using the following terms: (recurrence or death or survival) and (diabetes or T2DM) and (HCC or hepatocellular cancer or hepatocellular carcinoma or hepatoma). The search period was from 2000/01/01 to 2020/11/30.

The systematic qualitative review included only studies in English that involved human patients. Reports were excluded based on several criteria: a) data on animal models; b) studies that lacked enough clinical details; c) studies that had non-primary source data (eg, review articles, non-clinical studies, letters to the editor, expert opinions, and conference summaries). In the case of studies originating from the same center, the possible overlapping of clinical cases was examined, and the most informative study was considered eligible.

Data extraction and definitions

After a full-text review of the eligible studies, two independent authors (QL and FG) extracted the data and cross-checked all outcomes. During article selection and data extraction, potential discrepancies were resolved by a consensus with a third reviewer (AM). Collected data included the first author of the publication, year of publication, country, and the number of treated and recurred patients according to the different therapies adopted.

Quality assessment

Selected studies were systematically reviewed with the intent to identify potential sources of bias. The ar-

ticles' quality was assessed by using the Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool (17).

Statistical analysis

The results are expressed as odds ratio (OR) with 95% confidence intervals (CIs). The statistical heterogeneity was evaluated with the Higgins statistic squared (I²). I² values of 0%-25% were considered as an index of low heterogeneity between studies, 26%-50%: moderate heterogeneity, and ≥51%: high heterogeneity. The fixed-effects model was used when low or moderate (0%-50%) heterogeneity was detected between studies, while the random effects model was used when high heterogeneity was present. The value *P* < 0.05 indicated statistical significance. The meta-analysis was performed by using OpenMetaAnalyst (<http://www.cebm.brown.edu/openmeta/index.html>).

RESULTS

Search results and study characteristics

The PRISMA flow diagram schematically depicts the article selection process (Figure 1). Among the 1497 articles screened, 27 were included in this review (18-44). Of these,

8 (29.6%) were published from 2001 to 2009, and 19 (70.4%) during the last decade. Twenty-three articles (85.2%) were from Asia, of which 8 (29.6%) were from Taiwan, while 2 studies (7.4%) were from Europe, 1 (3.7%) was from North America, and 1 (3.7%) from Oceania (Figure 2).

Qualitative assessment of the included studies

All the 27 selected articles were retrospective analyses. As for the ROBINS-I tool quality assessment, all the studies had a low risk of bias.




FIGURE 2. Geographical distribution of the selected studies.




FIGURE 1. PRISMA diagram of the article selection process.

Review of the eligible studies

Details of the selected articles are reported in Tables 1-3. A total of 23 (85.2%) studies investigated the risk of death after any HCC treatment (Table 1) (18-27,29-37,40-42,44). Tumor recurrence was investigated in 14 (51.9%) studies (Table 2) (19,21,22,24,27,28,30,31,35,37,39-41,43), while the risk of progressive disease was reported in 7 (25.9%) studies (Table 3) (18,26,37,38,41,42,44). Overall, 5 (18.5%) studies had sample sizes of more than 1000 patients (25,34,37,41,44).

Death in HCC patients with vs without T2DM

Twenty-three studies reported post-treatment death rates in HCC patients with vs without T2DM (Table 1). Two studies contextually reported both data on post-hepatic resection and post-non-curative approach cases (21,37).

A total of 144 566 patients were considered, with 50 772 (35.1%) deaths. In detail, 24 815/36 689 (67.6%) and 25 957/107 877

(24.1%) deaths were observed in the T2DM and no-T2DM group, respectively. The selected studies showed great heterogeneity, with an $I^2=99.3%$ ($P<0.001$). Most of the studies showed a lower risk of death in T2DM absence (Figure 3). The summary OR showed an increased risk of death in T2DM patients, being 3.60 (95%CI 2.18-5.95; $P<0.001$).

Recurrence in HCC patients with vs without T2DM

Fourteen studies reported post-treatment recurrence rates in HCC patients with vs without T2DM (Table 2). A total of 40 021 patients were considered, with 13 469 (33.7%) recurrences. In detail, 3 609/10 641 (33.9%) and 9 860/29 462 (33.5%) recurrences were observed in the T2DM and no-T2DM group, respectively. The selected studies showed great heterogeneity, with an $I^2=79.1%$ ($P<0.001$). Most of the studies showed a lower risk of recurrence in T2DM absence (Figure 4). The summary OR showed an increased risk of recurrence in T2DM patients, being 1.30 (95%CI 1.03-1.63; $P=0.03$).

TABLE 1. Characteristics of included studies that assessed the risk of death in patients with hepatocellular carcinoma*

Ref.	First author	Year	City	Country	Study period	Design	N	Therapy	T2DM	N events	No T2DM	N events
17	Toyoda	2001	Ogaki	Japan	Jan 1990-Jun 1999	Retro	581	Mix	92	39	489	209
18	Poon	2002	Hong Kong	China	Jan 1989-Sep 1999	Retro	525	HR	62	29	463	229
19	Li	2003	Beijing	China	Jan 1998-Dec 2001	Retro	225	No surg	28	10	197	63
20	Huo	2004	Taipei	Taiwan	Apr 1996-March 2001	Retro	255	HR	41	23	214	85
							312	No surg	79	39	233	85
21	Komura	2007	Ishikawa	Japan	Jun 1987-May 2004	Retro	90	HR	30	17	60	14
22	Sumie	2007	Fukuoka	Japan	Jan 1994-Dec 2000	Retro	118	Mix	39	22	79	34
23	Kawamura	2008	Tokyo	Japan	Jan 1980-Dec 2006	Retro	40	HR/RFA	18	6	22	7
24	Huo	2009	Taipei	Taiwan	Jan 2002-Dec 2008	Retro	1713	Mix	392	235	1321	674
25	Feng	2010	Tainan City	Taiwan	Aug 2007-Jun 2008	Retro	52	TACE	14	2	38	6
26	Chen	2011	Taichung	Taiwan	Jul 2003-Jun 2009	Retro	135	RFA	53	26	82	19
28	Shau	2012	Taipei	Taiwan	Jan 2003-Dec 2004	Retro	931	Mix	185	96	746	248
29	Ting	2012	Taipei	Taiwan	Jan 2000-Dec 2008	Retro	389	HR	117	59	272	106
30	Hosokawa	2013	Tokyo	Japan	Jan 1999-Dec 2007	Retro	344	RFA	159	19	185	12
31	Bhat	2014	Rochester	USA	Jan 2005-Jun 2011	Retro	701	NA	263	170	438	257
32	Masood	2014	Lahore	Pakistan	Jun 2006-Dec 2012	Retro	282	Mix	97	50	185	95
33	Tsai	2014	Taichung	Taiwan	Jan 2000-Dec 2010	Retro	5924	HR	2962	41	2962	35
34	Wang	2014	Nanning	China	Jun 2003-Feb 2011	Retro	505	HR	134	1	371	8
35	Zhang	2014	Wuhan	China	Mar 2002-Aug 2012	Retro	138	TACE	34	34	104	102
36	Chan	2016	Taipei	Taiwan	Jan 1995-Dec 2011	Retro	26 267	HR	6 663	3 929	19 604	10 183
							91 482	No surg	21 449	18 931	70 034	61 539
39	Yoshida	2017	Tokyo	Japan	Jan 2001-Dec 2013	Retro	224	HR	112	41	112	33
40	Li	2018	Hangzhou	China	Jan 2008-Dec 2015	Retro	11 048	LT	3136	760	7912	1730
41	Liu	2018	Beijing	China	Jan 2005-Dec 2012	Retro	308	RFA	64	34	244	172
43	Liu	2020	Shanghai	China	Apr 2011-Jan 2017	Retro	1052	TACE	289	161	763	379
Total	-	-	-	-	-	-	144 566	-	36 689	24 815	107 877	25 957

*Abbreviations: Ref – reference; N – number; T2DM – type 2 diabetes mellitus; retro – retrospective; HR – hepatic resection; RFA – radiofrequency ablation; TACE – trans-arterial chemo-embolization; LT – liver transplantation.

Progressive disease in HCC patients with vs without T2DM

Seven studies reported post-treatment progressive disease rates in HCC patients with vs without T2DM (Table 3). A total of 109 564 patients were considered, with 23 246 (21.2%) progressive diseases. In detail, 6270/26 438 (23.7%) and 16 979/83 126 (20.4%) progressive diseases were observed in the T2DM and no-T2DM group, respectively. The selected studies showed heterogeneity, with an $I^2=59.6\%$ ($P=0.02$). Most of the studies showed a lower risk of progressive disease in T2DM absence (Figure 5). The summary OR showed an increased risk of progressive disease in T2DM patients, being 1.24 (95%CI = 1.09-1.41; $P=0.001$).

Death in HCC patients with vs without T2DM after curative or non-curative treatments

Thirteen studies reported death rates in HCC patients with vs without T2DM after a curative treatment, namely radiof-

requency ablation, hepatic resection, and transplantation (Table 1). A total of 46 054 patients were considered, with 17 618 (38.3%) deaths. In detail, 4985/13 551 (36.8%) and 12 633/32 503 (38.9%) deaths were observed in the T2DM and no-T2DM group, respectively. The selected studies showed great heterogeneity, with an $I^2=68.6\%$ ($P<0.001$). Most of the studies showed a lower risk of death in T2DM absence (Figure 6A). The summary OR showed an increased risk of death in T2DM patients after curative approach, being 1.30 (95%CI 1.09-1.54; $P=0.003$).

Six studies reported death rates in HCC patients with vs without T2DM after a non-curative treatment, namely any therapy other than radiofrequency ablation, hepatic resection, and transplantation. A total of 93 262 patients were considered, with 81 351 (87.2%) deaths. In detail, 19 177/21 893 (87.6%) and 62 174/71 369 (87.1%) deaths were observed in the T2DM and no-T2DM group, respectively. The selected studies showed great homogeneity,

TABLE 2. Characteristics of included studies that assessed the risk of hepatocellular carcinoma recurrence*

Ref.	First author	Year	City	Country	Study period	Design	N	Therapy	T2DM	N events	No T2DM	N events
18	Poon	2002	Hong Kong	China	Jan 1989-Sep 1999	Retro	525	HR	62	35	463	275
20	Huo	2004	Taipei	Taiwan	Apr 1996-March 2001	Retro	255	HR	41	18	214	104
21	Komura	2007	Ishikawa	Japan	Jun 1987-May 2004	Retro	90	HR	30	22	60	27
23	Kawamura	2008	Tokyo	Japan	Jan 1980-Dec 2006	Retro	40	HR/RFA	18	15	22	7
26	Chen	2011	Taichung	Taiwan	Jul 2003-Jun 2009	Retro	53	RFA	53	30	82	19
27	Howell	2011	Melbourne	Australia	Jan 2000-Aug 2007	Retro	135	Mix	58	17	77	19
29	Ting	2012	Taipei	Taiwan	Jan 2000-Dec 2008	Retro	389	HR	117	63	272	116
30	Hosokawa	2013	Tokyo	Japan	Jan 1999-Dec 2007	Retro	344	RFA	159	116	185	138
34	Wang	2014	Nanning	China	Jun 2003-Feb 2011	Retro	505	HR	134	57	371	175
36	Chan	2016	Taipei	Taiwan	Jan 1995-Dec 2011	Retro	26 267	HR	6663	2851	19 604	8380
38	Choi	2017	Busan	Korea	Jan 2010-Sep 2014	Retro	58	HR	14	8	44	12
39	Yoshida	2017	Tokyo	Japan	Jan 2001-Dec 2013	Retro	224	HR	112	69	112	74
40	Li	2018	Hangzhou	China	Jan 2008-Dec 2015	Retro	11 048	LT	3136	282	7912	489
42	Billeter	2020	Heidelberg	Germany	Oct 2001-Dec 2017	Retro	88	HR	44	26	44	25
Total	-	-	-	-	-	-	40 021	-	10 641	3 609	29 462	9 860

*Abbreviations: Ref – reference; N – number; T2DM – type 2 diabetes mellitus; retro – retrospective; HR – hepatic resection; RFA – radiofrequency ablation; LT – liver transplantation.

TABLE 3. Characteristics of included studies that assessed the risk of hepatocellular carcinoma progressive disease*

Ref.	Name	Year	City	Country	Study period	Design	N	Therapy	T2DM	N events	No T2DM	N events
17	Toyoda	2001	Ogaki	Japan	Jan 1990-Jun 1999	Retro	581	Mix	92	12	489	55
25	Feng	2010	Tainan City	Taiwan	Aug 2007-Jun 2008	Retro	52	TACE	14	6	38	6
36	Chan	2016	Taipei	Taiwan	Jan 1995-Dec 2011	Retro	91 482	No surg	21 449	5314	70 033	14 685
37	Di Costanzo	2016	Naples	Italy	Oct 2008-Jun 2014	Retro	313	Sorafenib	80	9	233	41
40	Li	2018	Hangzhou	China	Jan 2008-Dec 2015	Retro	15 776	Wait list	4450	674	11 326	1557
41	Liu	2018	Beijing	China	Jan 2005-Dec 2012	Retro	308	RFA	64	54	244	169
43	Liu	2020	Shanghai	China	Apr 2011-Jan 2017	Retro	1052	TACE	289	201	763	463
Total	-	-	-	-	-	-	109 564	-	26 438	6 270	83 126	16 976

*Abbreviations: Ref – reference; N – number; T2DM – type 2 diabetes mellitus; retro – retrospective; TACE – trans-arterial chemo-embolization; RFA – radiofrequency ablation.

with an $I^2=13\%$ ($P=0.33$). Most of the studies showed a lower risk of death in T2DM absence (Figure 6B). The summary OR showed an increased risk of death in T2DM patients after non-curative approach, being 1.05 (95%CI 1.00-1.10; $P=0.045$).

DISCUSSION

Our study found strong evidence that T2DM unfavorably affects HCC patients' outcomes in terms of progression and

recurrence of the disease and patients' survival after treatment, irrespective of the approach used.

HCC is a common malignancy with still unfavorable prognosis (45). Among the growing risk factors for its development are metabolic derangements associated with NASH and T2DM, with insulin resistance as a common denominator (46). In addition, NAFLD-related HCC occurs both in tandem and in the absence of underlying cirrhosis, substantiating NAFLD's tumorigenic effects (47,48). Accord-

Recurrence (T2DM vs. no T2DM)




FIGURE 3. Forest plot and meta-analysis of a disease recurrence after any hepatocellular carcinoma treatment: type 2 diabetes mellitus (T2DM) vs no-T2DM patients.

Death (T2DM vs. no T2DM)




FIGURE 4. Forest plot and meta-analysis of death after any hepatocellular carcinoma treatment: type 2 diabetes mellitus (T2DM) vs no-T2DM patients.

ing to epidemiologic studies, T2DM can increase the incidence of HCC and unfavorably alter the prognosis of patients with HCC (49).

In reference to its multisystemic effects, T2DM, in some centers, is considered a relative or absolute contraindication for curative treatments such as liver transplantation

HCC progression (T2DM vs. no T2DM) Random-effects





FIGURE 5. Forest plot and meta-analysis of progressive disease after any hepatocellular carcinoma treatment: type 2 diabetes mellitus (T2DM) vs no-T2DM patients.

A) Death (T2DM vs. no T2DM)

Curative approach (RFA, HR, LT)



B) Death (T2DM vs. no T2DM)

Non curative approach




FIGURE 6. Forest plot and meta-analysis of death after (A) curative hepatocellular carcinoma (HCC) treatments and (B) non-curative HCC treatments: type 2 diabetes mellitus (T2DM) vs no-T2DM patients.

due to poor outcomes and higher incidence of complications (50). Nevertheless, a recent meta-analysis showed that NAFLD-HCC patients could enjoy long-term survival benefits when treated with aggressive curative approaches (resection, transplantation, or thermo-ablation) with no difference in overall survival compared with non-NAFLD HCC patients (51). On the other hand, this meta-analysis provided solid evidence that T2DM patients compared with non-T2DM patients have an increased risk of death after curative HCC treatments, irrespective of the approach. Most out of 13 studies included in this meta-analysis showed a lower risk of death in T2DM absence. Furthermore, we demonstrated that the same T2DM impact on survival could also be expected after non-curative HCC approaches.

Most studies (85.2%) included in this meta-analysis were from Asia, where hepatitis B infection is still the leading cause of HCC. The incidence of alcohol- and HCV-related HCC in Asian countries is relatively stable and low, while NASH has become a growing epidemic with the prevalence of approximately 10%-20% (52,53). NASH is mainly accompanied by T2DM, dyslipidemia, and obesity, common factors leading to cardiovascular events. NASH is the fastest-growing cause of HCC in US liver transplant candidates (54), and the same is expected to occur in Asia due to changes in eating habits and sedentary lifestyles. NASH is strongly associated with HCC and liver-related mortality, yet the death in NAFLD is due mainly to cardiovascular diseases (55,56).

In addition, this meta-analysis shows that diabetes is inevitably associated with a greater risk of HCC progression. Only a study by Di Costanzo et al (38) showed longer time-to-progression (10 months vs 9 months) in 80 diabetic HCC patients treated with sorafenib compared with 233 non-diabetic HCC patients (38). Other six studies reporting data on HCC progression (17,25,36,40,41,43) showed an increased diabetes-associated risk (26 358 patients with vs 82 893 without diabetes) on HCC progression.

Overall, 14 included studies reported data on HCC recurrence (19,21,22,24,27,28,30,31,35,37,39-41,43). Robust evidence confirmed that diabetes increased HCC recurrence risk, irrespective of treatment. In the case of 508 out of 10 641 diabetic HCC patients included in the analysis, the risk of recurrence did not differ from that observed for non-diabetic HCC patients (19,21,31,35,40). Of note, the cause of HCC in the mentioned studies was mostly hepatitis virus-related.

In light of the observed results, it would be prudent to improve the prevention of T2DM by promoting a healthy diet and incorporating structured physical activity into everyday life (57). Moreover, an important role in the prevention of HCC can be played by interventions that lead to T2DM remission, such as those with glucagon-like peptide-1 receptor agonists (liraglutide and semaglutide) and bariatric surgery, which significantly reduce (>10%) and help maintain weight (58-61). The potential chemo-preventive effect of antidiabetic drugs such as metformin in HCC patients requires further clarification (62).

The present study has some limitations. First, a large part of the investigated population is from Asian countries. Therefore, the reported results should present some geographical peculiarities precluding their generalizability in Western populations. Further larger studies coming from North America and Europe are required. Another limitation relates to the great heterogeneity reported among different studies. Unfortunately, different aims and different approaches were reported in the examined studies, increasing the difficulty to obtain definitive results. We tried to minimize the heterogeneous effect by performing sub-analyses focused on specific classes of patients (ie, treated with curative vs non-curative therapies).

Further studies are required to better clarify the effect of T2DM in larger Western series and investigate the effect of anti-diabetic drugs in protecting against the risk of tumor evolution in HCC patients receiving curative or non-curative therapies.

Funding None.

Ethical approval Not required.

Declaration of authorship AM, MCB, and QL conceived and designed the study; FG and QL acquired the data; FG and QL analyzed and interpreted the data; AM and MCB drafted the manuscript; all authors critically revised the manuscript for important intellectual content; all authors gave approval of the version to be submitted; all authors agree to be accountable for all aspects of the work.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

- 1 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. *Clin Gastroenterol Hepatol*. 2012;10:1342-1359. e2. [Medline:23041539](https://pubmed.ncbi.nlm.nih.gov/23041539/) doi:10.1016/j.cgh.2012.10.001
- 2 Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja

- A, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. *Clin Gastroenterol Hepatol*. 2019;17:748-755.e3. [Medline:29908364](#) [doi:10.1016/j.cgh.2018.05.057](#)
- 3 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016;64:73-84. [Medline:26707365](#) [doi:10.1002/hep.28431](#)
 - 4 McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. *Clin Liver Dis*. 2011;15:223-43. vii-x. [Medline:21689610](#) [doi:10.1016/j.cld.2011.03.006](#)
 - 5 Zhang H, Gao C, Fang L, Yao SK. Increased international normalized ratio level in hepatocellular carcinoma patients with diabetes mellitus. *World J Gastroenterol*. 2013;19:2395-403. [Medline:23613635](#) [doi:10.3748/wjg.v19.i15.2395](#)
 - 6 Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. *Liver Int*. 2016;36:317-24. [Medline:26601627](#) [doi:10.1111/liv.13031](#)
 - 7 Nouredin M, Rinella ME. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. *Clin Liver Dis*. 2015;19:361-79. [Medline:25921668](#) [doi:10.1016/j.cld.2015.01.012](#)
 - 8 Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. *CA Cancer J Clin*. 2010;60:207-21. [Medline:20554718](#) [doi:10.3322/caac.20078](#)
 - 9 Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. *BMJ*. 2015;350:g7607. [Medline:25555821](#) [doi:10.1136/bmj.g7607](#)
 - 10 Wainwright P, Scorletti E, Byrne CD. Type 2 diabetes and hepatocellular carcinoma: risk factors and pathogenesis. *Curr Diab Rep*. 2017;17:20. [Medline:28290049](#) [doi:10.1007/s11892-017-0851-x](#)
 - 11 El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. *Clin Gastroenterol Hepatol*. 2006;4:369-80. [Medline:16527702](#) [doi:10.1016/j.cgh.2005.12.007](#)
 - 12 Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. *Diabetes Metab Res Rev*. 2012;28:109-22. [Medline:21898753](#) [doi:10.1002/dmrr.1291](#)
 - 13 Miele L, Bosetti C, Turati F, Rapaccini G, Gasbarrini A, La Vecchia C, et al. Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk. *Gastroenterol Res Pract*. 2015;2015:570356. [Medline:26074956](#) [doi:10.1155/2015/570356](#)
 - 14 Klil-Drori AJ, Azoulay L, Pollak MN. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? *Nat Rev Clin Oncol*. 2017;14:85-99. [Medline:27502359](#) [doi:10.1038/nrclinonc.2016.120](#)
 - 15 Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med*. 2015;162:777-84. [Medline:26030634](#) [doi:10.7326/M14-2385](#)
 - 16 Lai Q, Mennini G, Giovanardi F, Rossi M, Giannini EG. Immunglobulin, nucleos(t)ide analogues and hepatitis B virus recurrence after liver transplant: A meta-analysis. *Eur J Clin Invest*. 2021;e13575. [Medline:33866547](#) [doi:10.1111/eci.13575](#)
 - 17 Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919. [Medline:27733354](#) [doi:10.1136/bmj.i4919](#)
 - 18 Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriya S, et al. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. *Cancer*. 2001;91:957-63. [Medline:11251947](#) [doi:10.1002/1097-0142\(20010301\)91:5<957::AID-CNCR1085>3.0.CO;2-J](#)
 - 19 Poon RT, Fan ST, Wong J. Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? *Am J Gastroenterol*. 2002;97:1480-8. [Medline:12094870](#) [doi:10.1111/j.1572-0241.2002.05792.x](#)
 - 20 Li XP, Chen Z, Meng ZQ, Huang WX, Liu LM. Concurrent hyperglycemia does not influence the long-term prognosis of unresectable hepatocellular carcinomas. *World J Gastroenterol*. 2003;9:1848-52. [Medline:12918136](#) [doi:10.3748/wjg.v9.i8.1848](#)
 - 21 Huo TI, Wu JC, Lui WY, Huang YH, Lee PC, Chiang JH, et al. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. *Am J Gastroenterol*. 2004;99:1479-87. [Medline:15307864](#) [doi:10.1111/j.1572-0241.2004.30024.x](#)
 - 22 Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, et al. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. *Am J Gastroenterol*. 2007;102:1939-46. [Medline:17573788](#) [doi:10.1111/j.1572-0241.2007.01354.x](#)
 - 23 Sumie S, Kawaguchi T, Komuta M, Kuromatsu R, Itano S, Okuda K, et al. Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection. *Oncol Rep*. 2007;18:545-52. [Medline:17671700](#) [doi:10.3892/or.18.3.545](#)
 - 24 Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, et al. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. *J Gastroenterol Hepatol*. 2008;23:1739-46. [Medline:18713301](#) [doi:10.1111/j.1440-1746.2008.05436.x](#)
 - 25 Huo TI, Hsu CY, Huang YH, Hsia CY, Lin HC, Lee PC, et al. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. *Liver Int*. 2010;30:198-207. [Medline:19849777](#) [doi:10.1111/j.1478-3231.2009.02143.x](#)

- 26 Feng YH, Lin CY, Huang WT, Wu CL, Fang JL, Tsao CJ. Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma. *Med Oncol*. 2011;28:1080-8. [Medline:20734163](#) [doi:10.1007/s12032-010-9650-9](#)
- 27 Chen TM, Lin CC, Huang PT, Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. *J Gastroenterol Hepatol*. 2011;26:858-65. [Medline:21251068](#) [doi:10.1111/j.1440-1746.2011.06664.x](#)
- 28 Howell J, Yiu M, Gibson R, Thomson B, Stella D, Gorelik A, et al. Type 2 diabetes does not worsen prognosis in hepatocellular carcinoma. *Clin Res Hepatol Gastroenterol*. 2011;35:214-20. [Medline:21501980](#) [doi:10.1016/j.clinre.2010.11.002](#)
- 29 Shau WY, Shao YY, Yeh YC, Lin ZZ, Kuo R, Hsu CH, et al. Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. *Oncologist*. 2012;17:856-62. [Medline:22622151](#) [doi:10.1634/theoncologist.2012-0065](#)
- 30 Ting CT, Chen RC, Chen CC, Liu MH, Chu D, Kuo NW. Diabetes worsens the surgical outcomes in cirrhotic patients with hepatocellular carcinoma. *Tohoku J Exp Med*. 2012;227:73-81. [Medline:22688467](#) [doi:10.1620/tjem.227.73](#)
- 31 Hosokawa T, Kurosaki M, Tsuchiya K, Matsuda S, Muraoka M, Suzuki Y, et al. Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy. *World J Gastroenterol*. 2013;19:249-57. [Medline:23345948](#) [doi:10.3748/wjg.v19.i2.249](#)
- 32 Bhat M, Chaiteerakij R, Harmsen WS, Schleck CD, Yang JD, Giama NH, et al. Metformin does not improve survival in patients with hepatocellular carcinoma. *World J Gastroenterol*. 2014;20:15750-5. [Medline:25400459](#) [doi:10.3748/wjg.v20.i42.15750](#)
- 33 Masood MA, Zafar W, Yusuf MA. Is diabetes mellitus a poor prognostic factor for hepatocellular carcinoma? *J Gastrointest Cancer*. 2014;45:448-51. [Medline:24961202](#) [doi:10.1007/s12029-014-9631-x](#)
- 34 Tsai MS, Lin CL, Chang SN, Lee PH, Kao CH. Diabetes mellitus and increased postoperative risk of acute renal failure after hepatectomy for hepatocellular carcinoma: a nationwide population-based study. *Ann Surg Oncol*. 2014;21:3810-6. [Medline:24841349](#) [doi:10.1245/s10434-014-3777-4](#)
- 35 Wang YY, Huang S, Zhong JH, Ke Y, Guo Z, Liu JQ, et al. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma after curative hepatectomy. *PLoS One*. 2014;9:e113858. [Medline:25436613](#) [doi:10.1371/journal.pone.0113858](#)
- 36 Zhang J, Gong F, Li L, Zhao M, Song J. Diabetes mellitus and the neutrophil to lymphocyte ratio predict overall survival in non-viral hepatocellular carcinoma treated with transarterial chemoembolization. *Oncol Lett*. 2014;7:1704-10. [Medline:24765205](#) [doi:10.3892/ol.2014.1896](#)
- 37 Chan KM, Kuo CF, Hsu JT, Chiou MJ, Wang YC, Wu TH, et al. Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection. *Liver Int*. 2017;37:434-41. [Medline:27775209](#) [doi:10.1111/liv.13280](#)
- 38 Di Costanzo GG, Tortora R, Morisco F, Addario L, Guarino M, Cordone G, et al. Impact of diabetes on outcomes of sorafenib therapy for hepatocellular carcinoma. *Target Oncol*. 2017;12:61-7. [Medline:27503006](#) [doi:10.1007/s11523-016-0454-5](#)
- 39 Choi Y, Choi Y, Choi CS, Lee YH. Diabetes mellitus increases the risk of intrahepatic recurrence of hepatocellular carcinoma after surgical resection. *Tumori*. 2017;103:279-85. [Medline:28085178](#) [doi:10.5301/tj.5000594](#)
- 40 Yoshida N, Midorikawa Y, Higaki T, Nakayama H, Tsuji S, Matsuoka S, et al. Diabetes mellitus not an unfavorable factor on the prognosis of hepatitis C virus-related hepatocellular carcinoma. *Hepatol Res*. 2018;48:28-35. [Medline:28258663](#) [doi:10.1111/hepr.12888](#)
- 41 Li Z, Gao Z, Xiang J, Zhou J, Yan S, Hu Z. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: The impact of pre-existing diabetes mellitus. *Liver Int*. 2019;39:361-70. [Medline:30276959](#) [doi:10.1111/liv.13982](#)
- 42 Liu SR, Chao R, Liang P, Yu XL, Cheng ZG, Han ZY. Diabetes mellitus may worsen the prognosis in hepatocellular carcinoma patients undergoing curative microwave ablation. *J BUON*. 2018;23:958-64. [Medline:30358199](#)
- 43 Billeter AT, Müller PC, Albrecht T, Roessler S, Löffler M, Lemekhova A, et al. Impact of type 2 diabetes on oncologic outcomes of hepatocellular carcinomas in non-cirrhotic, non-alcoholic steatohepatitis: a matched-pair analysis. *J Gastrointest Surg*. 2020. [Medline:32378092](#)
- 44 Liu G, Xia F, Fan G, Yu J, Bao L, Zhang C, et al. Type 2 diabetes mellitus worsens the prognosis of intermediate-stage hepatocellular carcinoma after transarterial chemoembolization. *Diabetes Res Clin Pract*. 2020;169:108375. [Medline:32827592](#) [doi:10.1016/j.diabres.2020.108375](#)
- 45 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136:E359-86. [Medline:25220842](#) [doi:10.1002/ijc.29210](#)
- 46 Jinjuvadia R, Patel S, Liangpunsakul S. The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. *J Clin Gastroenterol*. 2014;48:172-7. [Medline:24402120](#) [doi:10.1097/MCG.0b013e3182a030c4](#)
- 47 Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. *Int J Cancer*. 2011;128:2436-43. [Medline:21128245](#) [doi:10.1002/ijc.25797](#)
- 48 Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US Experience. *Dig Dis Sci*. 2015;60:3142-8. [Medline:26250831](#) [doi:10.1007/s10620-015-3821-7](#)

- 49 Ali Kamkar MM, Ahmad R, Alsmadi O, Behbehani K. Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review. *J Diabetes Metab Disord*. 2014;13:57. [Medline:24918094](#) [doi:10.1186/2251-6581-13-57](#)
- 50 Thuluvath PJ. When is diabetes mellitus a relative or absolute contraindication to liver transplantation? *Liver Transpl*. 2005;(Suppl 2):S25-9. [Medline:16237683](#) [doi:10.1002/lt.20606](#)
- 51 Chin KM, Prieto M, Cheong CK, Di Martino M, Ielpo B, Goh BKP, et al. Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a meta-analysis and review of current literature. *HPB (Oxford)*. 2021;S1365-182X(21)00025-3.
- 52 Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. *J Hepatol*. 2017;67:862-73. [Medline:28642059](#) [doi:10.1016/j.jhep.2017.06.003](#)
- 53 Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. *Lancet Gastroenterol Hepatol*. 2020;5:167-228. [Medline:31852635](#) [doi:10.1016/S2468-1253\(19\)30342-5](#)
- 54 Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. *Clin Gastroenterol Hepatol*. 2019;17:748-755.e3. [Medline:29908364](#) [doi:10.1016/j.cgh.2018.05.057](#)
- 55 Chiriac S, Stanciu C, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, et al. Nonalcoholic fatty liver disease and cardiovascular diseases: the heart of the matter. *Can J Gastroenterol Hepatol*. 2021;2021:6696857. [Medline:33505944](#) [doi:10.1155/2021/6696857](#)
- 56 Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. *J Hepatol*. 2008;49:608-12. [Medline:18682312](#) [doi:10.1016/j.jhep.2008.06.018](#)
- 57 Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care*. 1997;20:537-44. [Medline:9096977](#) [doi:10.2337/diacare.20.4.537](#)
- 58 Iepsen EW, Lundgren J, Dirksen C, Jensen JE, Pedersen O, Hansen T, et al. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. *Int J Obes*. 2015;39:834-41. [Medline:25287751](#) [doi:10.1038/ijo.2014.177](#)
- 59 Ahrén B, Atkin SL, Charpentier G, Warren ML, Wilding JPH, Birch S, et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. *Diabetes Obes Metab*. 2018;20:2210-9. [Medline:29766634](#) [doi:10.1111/dom.13353](#)
- 60 Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet*. 2021;397:971-84. [Medline:33667417](#) [doi:10.1016/S0140-6736\(21\)00213-0](#)
- 61 Park JY. Prediction of Type 2 diabetes remission after bariatric or metabolic surgery. *J Obes Metab Syndr*. 2018;27:213-22. [Medline:31089566](#) [doi:10.7570/jomes.2018.27.4.213](#)
- 62 Cho WR, Wang CC, Tsai MY, Chou CK, Liu YW, Wu YJ, et al. Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients. *PLoS One*. 2021;16:e0247231. [Medline:33661912](#) [doi:10.1371/journal.pone.0247231](#)